Drug Database
PR

prednisolone farnesil (Farnezone / Farnesone / Farnerate)

✓ Approved

SK · NR3C1 · 小分子

什么是 prednisolone farnesil?

prednisolone farnesil 是一种小分子,由SK研发。该药已获批,用于治疗相关适应症,给药途径:Topical。

药物档案

商品名Farnezone, Farnesone, Farnerate
公司SK
药物类别小分子
分子靶点NR3C1
给药途径Topical
状态Approved

作用机制

分子靶点

prednisolone farnesil 作用于 1 个分子靶点:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

prednisolone farnesil 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Musculoskeletal and connective tissue disordersRheumatoid arthritis✓ Approved

相关研究文献

PubMedJournal of pediatric gastroenterology and nutrition2026-11-17

Treatment of pediatric autoimmune liver disease beyond prednisolone and azathioprine in a cohort of 115 patients.

Korell Marie M, Kramer Miriam M, Poets Alina A, Mutschler Frauke F et al.

Pediatric autoimmune hepatitis (pAIH) is an acute or chronic inflammatory liver disease, caused by a dysregulation of the immune system. Autoimmune sclerosing cholangitis (ASC) additionally affects the bile ducts. Traditional first-line treatment (FLT) consists of prednisolone and azathioprine. If pAIH/ASC remains untreated or biochemical remission (BR) is not achieved, end-stage liver disease develops. We aimed to analyze the 6-months-outcomes of various second- and third-line therapies for pAIH/ASC. This is a retrospective single-center analysis, including all cases of patients with pAIH or ASC between 2000 and 2025. All patients were diagnosed based on published European Society for Paediatric Gastroenterology, Hepatology and Nutrition diagnostic criteria. Of 115 patients with pAIH or ASC, 26 patients required an alternative therapy (altT) other than prednisolone and azathioprine, most of them due to non-BR, including due to non-compliance. The 6-month outcome shows, that tumor necrosis factor (TNF)-alpha inhibitors overall achieved the best results with a BR rate of 40% (n = 2/5). This was closely followed by cyclosporin A (CSA), with a BR rate of 36.4% (n = 4/11), which was the most commonly used drug in our study. Patients with inflammatory bowel disease are significantly more likely to need altT. The overall BR rate 6 months after start of altT is low and decreases with each stage of therapy, the TNF-alpha inhibitors demonstrated the highest BR rate for altT. Non-compliance is a significant problem in general, so it is unclear whether the success of this therapy is solely attributable to the drug's inherent immunomodulatory function or to its controlled administration via intravenous injection. The prospective evaluation of this novel, low-side-effect management option warrants further explorations.

PMID 43042670
阅读全文 →
PubMedCureus2026-11-17

Acquired Hemophilia A: A Case Report and Literature Review on a Diagnostic and Therapeutic Conundrum.

Stanley Ann M AM, Kakkar Shruti S, Chugh Sanjoli S, Mittal Tushar T et al.

Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder in which the body spontaneously produces inhibitory antibodies against coagulation factor VIII. This leads to severe, potentially life-threatening bleeding in patients who have no personal or family history of bleeding problems. The condition carries substantial mortality and remains difficult to diagnose and treat, especially in resource-limited settings. Here, we present three consecutive patients with AHA who were managed at a tertiary hematology center in northern India between 2016 and 2026. Each case illustrates a clinically distinct presentation and a different treatment course. The first patient was a 24-year-old man with pemphigus foliaceus and a history of Castleman disease previously treated with rituximab. Hemostasis was achieved with factor eight inhibitor bypassing activity (FEIBA), an activated prothrombin complex concentrate, but he developed refractory disease, with his inhibitor titer rising more than 20-fold from 16 to 332 Bethesda units (BU) despite first-line prednisolone and cyclophosphamide, after which second-line rituximab was started. Emicizumab was recommended for long-term hemostatic prophylaxis, but the patient was unable to access it due to financial constraints, and he was subsequently lost to follow-up. The second patient was a 35-year-old previously healthy man who presented with a post-traumatic popliteal hematoma and hematuria. Following treatment with prednisolone and cyclophosphamide, the inhibitor became undetectable at eight months, and he was in clinical remission; complete remission could not be confirmed because factor VIII activity was not reassessed. He was subsequently lost to follow-up. The third patient was a 75-year-old woman with longstanding diabetes mellitus and hypertension. She presented with a sudden-onset sublingual hematoma, and high-resolution computed tomography (HRCT) confirmed epiglottic and hypopharyngeal wall thickening causing narrowing of the supraglottic airway. Hemostasis was achieved with FEIBA, alongside prednisolone and subsequent outpatient rituximab, and she was discharged. Approximately four months after discharge, and at least four months after the last FEIBA dose, she suffered an acute myocardial infarction, and her family subsequently chose comfort-focused care. This report underscores the wide clinical variability of AHA, the importance of thorough coagulation workup in any unexplained bleeding episode, the difficulties of managing refractory inhibitor disease in resource-limited settings, and the critical value of HRCT when evaluating hematomas located near the airway.

PMID 43041933
阅读全文 →
PubMedCureus2026-11-17

Progesterone Dermatitis (Progestogen Hypersensitivity) Presenting as a Polymorphic Drug Eruption After Oral Norethisterone: A Case Report.

Singh Ishika I, Vatve Maneesha M

Progestogen hypersensitivity (PH) describes hypersensitivity reactions to endogenous progesterone, classically termed autoimmune progesterone dermatitis, or to exogenous progestogens. Non-cyclical presentations can be difficult to distinguish from other dermatoses. We describe a case of a 46-year-old woman who developed a widespread pruritic rash 52 days after starting oral norethisterone for heavy menstrual bleeding. The rash began on her arms and progressed to involve the trunk and legs, with papules, pustules, confluent erythema, and crusting. Purpuric, targetoid lesions later developed on her lower legs, followed by pompholyx-like vesicles on her palms and a periorbital eczematous rash. Her eosinophil count was 1.2×109/L (normal range: 0.02-0.50x109/L) and C-reactive protein 16 mg/L (normal range: <5 mg/L). She was afebrile, with no mucosal involvement and no evidence of hepatic or renal dysfunction at presentation. Herpes simplex and varicella-zoster PCR were negative. Skin biopsy showed acanthosis, parakeratosis, and spongiosis, with a dermal infiltrate of lymphocytes and eosinophils. The clinical differentials included a drug eruption, pustular folliculitis, atypical pityriasis rubra pilaris, and erythema multiforme. Norethisterone was stopped, and she was treated with potent topical corticosteroids and a six-week tapering course of oral prednisolone, starting at 30 mg daily. Her skin was largely clear about nine weeks after norethisterone was stopped, with no relapse to date. Discussion at the clinicopathological meeting concluded that this was a delayed-type hypersensitivity reaction to norethisterone, consistent with exogenous PH. She declined a progesterone challenge and was advised to avoid progestogen-containing hormone therapy. This case describes a polymorphic, non-cyclical presentation of PH caused by an oral synthetic progestogen. It may complicate future management of menopausal symptoms, as women with an intact uterus usually require a progestogen alongside estrogen therapy to protect the endometrium.

PMID 43042198
阅读全文 →
PubMedClinical medicine insights. Case reports2026-11-16

Resolution of Corticosteroid-Refractory Autoimmune Hepatitis Type 1 Using a Standardized Boswellia serrata Extract: A Case Report and T-Regulatory Cell Phenotyping.

Fernando Anushka A, Adi Mohammad M, Ashraf Ahmed A

Autoimmune hepatitis (AIH) is a chronic immune-mediated liver disease typically treated with corticosteroids and azathioprine. However, some patients develop corticosteroid dependence or intolerance to conventional steroid-sparing immunosuppressive agents, highlighting the need for alternative therapeutic approaches. A 47-year-old woman with corticosteroid-dependent AIH type 1 experienced biochemical relapse during prednisolone tapering and was intolerant to both azathioprine and mycophenolate mofetil. Adjunctive therapy with a standardized Boswellia serrata extract (300 mg three times daily) was initiated during a structured corticosteroid taper. Within 12 weeks, alanine aminotransferase normalized (268 to 32 U/L), immunoglobulin G decreased from 22.4 to 12.1 g/L, and prednisolone was successfully reduced from 30 to 5 mg/day without relapse. Flow cytometry demonstrated a change in the Treg/Th17 ratio from 0.4 to 1.2. Biochemical remission was maintained at 18 months without treatment-related adverse events. Standardized Boswellia serrata extract may represent a potential adjunctive steroid-sparing therapy for selected patients with refractory or treatment-intolerant autoimmune hepatitis. This observation is hypothesis-generating and does not establish causality. Prospective controlled studies are needed to confirm its efficacy, safety, and immunomodulatory role.

PMID 43036416
阅读全文 →
PubMedCureus2026-11-16

Remission of Widespread Erythema Annulare Centrifugum After Empiric Oral Fluconazole in a 54-Year-Old Woman: A Case Report.

Bakhsh Sehrish S, Almazied Mohammad M, Alghudifi Ohud O, Alammari Fares F

Erythema annulare centrifugum (EAC) is a rare reactive dermatosis that can be difficult to manage in persistent cases. A 54-year-old woman presented with pruritic, annular, and polycyclic plaques that subsequently extended to the neck, trunk, upper back, hands, lower legs, and feet. A skin biopsy supported the diagnosis of superficial EAC on clinicopathologic correlation. After limited improvement with topical therapies and oral prednisolone, she received four weekly doses of empiric oral fluconazole 150 mg without adverse effects. The eruption improved, and approximately five months after treatment discontinuation, she remained clear apart from residual post-inflammatory hyperpigmentation. The temporal association suggests a possible treatment response; however, the absence of pretreatment mycologic testing and the possibility of spontaneous remission limit causal interpretation.

PMID 43036652
阅读全文 →
PubMedCureus2026-11-16

Neurological Masquerades of Diffuse Large B-cell Lymphoma: A Case Mimicking Motor Neurone Disease.

Shams Ibnul I, Tuhin Rayhanul I RI, Abir Habib Ullah HU, Khan Md Romman MR

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) and typically presents with lymphadenopathy, constitutional symptoms, or extranodal disease. Neurological presentations are uncommon and may mimic primary neurological disorders, which creates significant diagnostic challenges. A 67-year-old woman presented with progressive lower back pain, paraesthesia affecting all four limbs that left her bed-bound, faecal incontinence, dysphagia, weight loss, and evolving neurological deficits, including left-sided facial weakness and asymmetric tetraparesis predominantly affecting the left side. Initial neuroimaging demonstrated no acute intracranial pathology and no evidence of spinal cord compression. Electromyography (EMG) revealed widespread active and chronic denervation, which suggested an anterior horn cell disorder or motor neurone disease (MND). However, the presence of sensory symptoms, constitutional features, and progressive clinical deterioration prompted further investigation. CT of the chest, abdomen, and pelvis identified cervical and retroperitoneal lymphadenopathy. Ultrasound-guided lymph node biopsy confirmed DLBCL. Cerebrospinal fluid (CSF) analysis did not demonstrate definitive evidence of central nervous system (CNS) lymphoma. After six cycles of polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisolone (Pola-R-CHP), the patient achieved complete metabolic remission and showed substantial improvement in her neurological symptoms. This case highlights the importance of maintaining a broad differential diagnosis in patients presenting with atypical neurological syndromes. DLBCL may rarely present with neurological features that mimic MND. Although a definitive paraneoplastic neurological syndrome (PNS) could not be established, a possible paraneoplastic neurological process was considered. Recognition of systemic red-flag features, such as weight loss and lymphadenopathy, was pivotal in reaching the correct diagnosis.

PMID 43036619
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多prednisolone farnesil